Please login to the form below

Not currently logged in
Email:
Password:

Valeant acquires GSK's Zovirax

Valeant Pharmaceuticals' Biovail Laboratories has signed a deal under which it will acquire all US and Canadian rights to certain formulations of GSK's Zovirax

Valeant Pharmaceuticals' Biovail Laboratories has signed a deal under which it will acquire all US and Canadian rights to non-ophthalmic topical formulations of GlaxoSmithKline's (GSK) herpes drug Zovirax (acyclovir) for $300m.

Biovail was already the exclusive distributor of the product in the US, where the deal will allow the company to keep more of the profits from the drug. Biovail did not previously have rights to the drug in Canada.

"The current distribution agreement between GSK and Biovail was problematic for both companies and this new arrangement should solve this issue for both organisations,” Valeant CEO J Michael Pearson said in a statement.  "We believe that our sales and marketing organisations in the United States and Canada have the ability to revitalise and grow the brand."

Zovirax ointment and cream are indicated for genital herpes and cold sores. Biovail paid $133m for the marketing rights to the topical formulations of Zovirax in a ten-year deal signed between the companies in 2001. In late 2002, Biovail announced that it had extended its existing 10-year agreement with GSK for the marketing rights to 20 years for an additional payment of $40m.

4th February 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics